Dare Bioscience Inc (NASDAQ:DARE) Q1 2020 Earnings Conference Call - Preliminary Transcript
May 14, 2020 • 04:30 pm ET
Welcome to the conference call hosted by Dare Bioscience to review the Company's Financial Results for the Quarter Ended March 31, 2020, and to provide a general business update. This call is being recorded. My name is Victor, and I will be your operator today. With us today are Sabrina Martucci Johnson, Dare's President and Chief Executive Officer; John Fair, Dare's Chief Strategy Officer; and Lisa Walters-Hoffert, Dare's Chief Financial Officer. Ms. Johnson, please proceed.
Sabrina Martucci Johnson
Thank you, and welcome to our financial results and business update call for Dare Bioscience. We are looking forward to discussion our first quarter results and highlighting the recent development and anticipated milestones for 2020 and beyond.
Before we begin, I'd like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Any statements made during this call that are not statements of historical fact should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements.
Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed on March 27, 2020. And our quarterly report on Form 10-Q for the quarter ended March 31, 2020 which is filed today.
I'd also like to point out that the content in this call includes time-sensitive information that is current only as of today, May 14, 2020. Dare undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law.
So as you know, Dare is a biopharmaceutical company squarely focused on improving the life and wellbeing of women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Our value creation strategy is to accelerate availability of new prescription products in women's health by selecting and advancing product candidates that we believe have the potential to be first-in-category and first-line.
On our last call we discuss the impact of the COVID-19 pandemic on our general business operation, as well as our anticipated clinical and regulatory milestone. As we discussed we believe the uniqueness of our business model allow use to react quickly to changes in circumstances.
And since then, we have maintain the case of our product development and regulatory activities necessary to remain on track to achieve the clinical and regulatory objectives we discuss, namely, we remain on tract to conduct and report topline results this year for Phase 3 clinical trial of DARE-BV1 for the treatment of bacterial vaginosis.
A condition estimated to impact over 20 million in the U.S. alone. We are also confirming our prior guidance with respect to our Sildenafil Cream program. We expect to report topline